AVRO AVROBIO Inc

Price (delayed)

$5.96

Market cap

$259.99M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.12

Enterprise value

$33.06M

AVROBIO's vision is to bring personalized gene therapy to the world. The company aims to prevent, halt or reverse disease throughout the body with a single dose of gene therapy ...

Highlights
AVRO's net income is down by 30% year-on-year and by 2.1% since the previous quarter
AVROBIO's quick ratio has decreased by 27% from the previous quarter and by 16% YoY

Key stats

What are the main financial stats of AVRO
Market
Shares outstanding
43.62M
Market cap
$259.99M
Enterprise value
$33.06M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.13
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$123.2M
EBITDA
-$121.99M
Free cash flow
-$104.11M
Per share
EPS
-$3.12
Free cash flow per share
-$2.45
Book value per share
$5.29
Revenue per share
$0
TBVPS
$5.6
Balance sheet
Total assets
$238.1M
Total liabilities
$17.1M
Debt
$0
Equity
$220.99M
Working capital
$216.57M
Liquidity
Debt to equity
0
Current ratio
13.77
Quick ratio
13.39
Net debt/EBITDA
1.86
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-49.9%
Return on equity
-53.8%
Return on invested capital
N/A
Return on capital employed
-55.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVRO stock price

How has the AVROBIO stock price performed over time
Intraday
-0.33%
1 week
-4.18%
1 month
-4.94%
1 year
-56.14%
YTD
-57.25%
QTD
-32.96%

Financial performance

How have AVROBIO's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$123.04M
Net income
-$123.2M
Gross margin
N/A
Net margin
N/A
AVRO's net income is down by 30% year-on-year and by 2.1% since the previous quarter
AVRO's operating income is down by 27% year-on-year and by 2.1% since the previous quarter

Growth

What is AVROBIO's growth rate over time

Valuation

What is AVROBIO stock price valuation
P/E
N/A
P/B
1.13
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 9% year-on-year
AVRO's price to book (P/B) is 46% less than its last 4 quarters average of 2.1
AVROBIO's equity has decreased by 8% YoY and by 5% from the previous quarter

Efficiency

How efficient is AVROBIO business performance
AVROBIO's ROE has decreased by 26% YoY and by 4.3% from the previous quarter
The return on assets has declined by 24% year-on-year and by 4% since the previous quarter

Dividends

What is AVRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVRO.

Financial health

How did AVROBIO financials performed over time
The total liabilities rose by 32% QoQ and by 8% YoY
AVRO's current ratio is down by 27% QoQ and by 15% YoY
AVRO's debt is 100% smaller than its equity
AVROBIO's equity has decreased by 8% YoY and by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.